Bio-Techne Corp (NASDAQ: TECH) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Bio-Techne Corp to similar businesses based on the strength of its valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Institutional & Insider Ownership

98.4% of Bio-Techne Corp shares are held by institutional investors. Comparatively, 48.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 3.4% of Bio-Techne Corp shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Bio-Techne Corp and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Techne Corp 0 2 3 0 2.60
Bio-Techne Corp Competitors 798 2967 6487 146 2.58

Bio-Techne Corp currently has a consensus target price of $126.33, indicating a potential upside of 3.36%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 4.14%. Given Bio-Techne Corp’s rivals higher probable upside, analysts clearly believe Bio-Techne Corp has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Bio-Techne Corp and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Bio-Techne Corp $563.00 million $186.35 million 63.01
Bio-Techne Corp Competitors $207.80 million -$2.20 million -0.21

Bio-Techne Corp has higher revenue and earnings than its rivals. Bio-Techne Corp is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Bio-Techne Corp has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Bio-Techne Corp’s rivals have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Bio-Techne Corp and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bio-Techne Corp 12.93% 14.19% 8.43%
Bio-Techne Corp Competitors -3,991.27% -119.32% -44.10%

Dividends

Bio-Techne Corp pays an annual dividend of $1.28 per share and has a dividend yield of 1.0%. Bio-Techne Corp pays out 66.0% of its earnings in the form of a dividend. As a group, “Biotechnology & Medical Research” companies pay a dividend yield of 1.0% and pay out 66.0% of their earnings in the form of a dividend.

Summary

Bio-Techne Corp beats its rivals on 8 of the 13 factors compared.

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.